Biotech News
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
ir.olema.com2026-05-06 15:02 EST
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients